Should Liver Transplantation in Patients with Model for End-Stage Liver Disease Scores <= 14 Be Avoided? A Decision Analysis Approach

Division of Transplantation, Department of Surgery, University of Washington, Seattle, WA 98195, USA.
Liver Transplantation (Impact Factor: 4.24). 02/2009; 15(2):242-54. DOI: 10.1002/lt.21703
Source: PubMed


Studies have shown that liver transplantation offers no survival benefits to patients with Model for End-Stage Liver Disease (MELD) scores <or= 14 in comparison with remaining on the waitlist. The consensus of a 2003 transplant community national conference was that a minimum MELD score should be required for placement on the liver waitlist, but no minimum listing national policy was enacted at that time. We developed a Markov microsimulation model to compare results under the present US liver allocation policy with outcomes under a "Rule 14" policy of barring patients with a MELD score of <or=14 from the waitlist or transplantation. For probabilities in the microsimulation model, we used data on all adult patients (>or=18 years) listed for or undergoing primary liver transplantation in the United States for chronic liver disease from 1/1/2003 through 12/31/2007 with follow-up until 2/1/2008. The "Rule 14" policy gave a 3% improvement in overall patient survival over the present system at 1, 2, 3, and 4 years and predicted a 13% decrease in overall waitlist time for patients with MELD scores of 15 to 40. Patients with the greatest benefit from a "Rule 14" policy were those with MELD scores of 6 to 10, for whom a 17% survival advantage was predicted from waiting on the list versus undergoing transplantation. Our analysis supports changing the national liver allocation policy to not allow liver transplantation for patients with MELD <or= 14.

Download full-text


Available from: James D Perkins, Nov 10, 2014
  • Source
    • "Regarding other indications for LT, recent analyses have shown a survival benefit only for patients with MELD scores above 15 at the time of transplantation [87] [88] [89]; however, there is still debate "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nodular regenerative hyperplasia (NRH) is the leading cause of non-cirrhotic portal hypertension in Western countries. Although some patients are successfully managed medically or with shunting procedures, others require liver transplantation. The aim of this review was to assess the overall results obtained with liver transplantation and to better define its role in this setting. Systematic review of all published studies on liver transplantation for NRH without language restrictions, in Medline, Embase and Cochrane Library databases through March 2010. 17 studies including a total of 73 patients were identified; 47 (64.3%) were excluded due to lacking inclusion criteria or clinical data and 26 (35.7%) were analysed. Before liver transplantation, the most frequent clinical presentation was gastroesophageal bleeding (65.3%) followed by ascites (61.5%), hepatic encephalopathy (30.7%) and liver failure (11.5%). The mean follow-up reported after liver transplantation was 30.6±27.6 months and patient and graft survival rate was 78.3%. Only one case reported a NRH recurrence 7 years after liver transplantation (LT). Although there are no hard data supporting the role of liver transplantation in symptomatic NRH, onset of severe portal hypertension in this setting may represent a valid indication.
    Full-text · Article · May 2011 · Digestive and Liver Disease
  • [Show abstract] [Hide abstract]
    ABSTRACT: Donor–recipient matching is an important factor influencing the outcome of liver transplantation (LT), especially when, due to organ shortage, extended criteria donors (ECD) are used. Among donor risk factors, donor age has been associated with severe HCV recurrence after LT, and severe steatosis increases the risk of NAFLD after LT and impairs liver regeneration when partial liver is used. Grafts from HCV positive donors can be used (in absence of fibrosis) in HCV positive recipients; however, attention should be paid when donor age is over 50. Anti-HB core positive grafts are used in patients with HBsAg or anti-HBc patients with long term prophylaxis to prevent recurrence. The use of partial (living or cadaveric) livers is marginal in western countries but seems not to worsen prognosis. Decision whether to allocate ECD to sickest or healthiest recipients is still a matter of debate in terms of outcome and utility, therefore dedicated studies are needed.
    No preview · Article · Dec 2009 · Digestive and Liver Disease Supplements
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary transplantation offers longer life-expectancy in comparison to hepatic resection (HR) for hepatocellular carcinoma (HCC) followed by salvage transplantation; however, livers not used for primary transplantation can be reallocated to the remaining waiting-list patients, thus, the harm caused to resected patients could be balanced, or outweighed, by the benefit obtained from reallocation of livers originating from HCC patients first being resected. A Markov model was developed to investigate this issue based on literature data or estimated from the United Network for Organ Sharing database. Markov model shows that primary transplantation offers longer life-expectancy in comparison to HR and salvage transplantation if 5-year posttransplant survival remains higher than 60%. The balance between the harm for resected patients and the benefit for the remaining waiting list depends on (a) the proportion of HCC candidates, (b) the percentage shifted to HR and (c) the median expected time-to-transplant.
    Full-text · Article · Jun 2010 · American Journal of Transplantation
Show more